Automated digital TIL analysis (ADTA) adds prognostic value to standard assessment of depth and ulceration in primary melanoma

Noninvasive prediction of lymph node status for patients with early-stage cervical cancer based on radiomics features from ultrasound images

(2020) Xiance Jin et al.   EUROPEAN RADIOLOGY

Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II-III Melanoma

(2019) Robyn D. Gartrell et al.   CLINICAL CANCER RESEARCH

Biomarkers Predictive of Survival and Response to Immune Checkpoint Inhibitors in Melanoma

(2019) Emanuelle M. Rizk et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Practice Patterns and Prognostic Value of Sentinel Lymph Node Biopsy for Thick Melanoma: A National Cancer Database Study

(2019) Yun Song et al.   ANNALS OF SURGICAL ONCOLOGY

Deep learning based on standard H&E images of primary melanoma tumors identifies patients at risk for visceral recurrence and death

(2019) Prathamesh M. Kulkarni et al.   CLINICAL CANCER RESEARCH

An open source automated tumor infiltrating lymphocyte algorithm for prognosis in melanoma

(2019) Balazs Acs et al.   Nature Communications

Tumour‐infiltrating lymphocytes in canine melanocytic tumours: An investigation on the prognostic role of CD3 + and CD20 + lymphocytic populations

(2019) Ilaria Porcellato et al.   Veterinary and Comparative Oncology

The prognostic significance of tumor-infiltrating lymphocytes for primary melanoma varies by sex

(2018) Andrew J. Sinnamon et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

(2018) Alexander M.M. Eggermont et al.   NEW ENGLAND JOURNAL OF MEDICINE

Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images

(2018) Joel Saltz et al.   Cell Reports

Quantitative Analysis of Immune Infiltrates in Primary Melanoma

(2018) Robyn D. Gartrell et al.   Cancer Immunology Research

Update on eighth edition American Joint Committee on Cancer classification for cutaneous melanoma and overview of potential pitfalls in histological examination of staging parameters

(2018) Celestine M Trinidad et al.   JOURNAL OF CLINICAL PATHOLOGY

Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival

(2017) Bernhard Mlecnik et al.   JNCI-Journal of the National Cancer Institute

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

(2017) Jeffrey Weber et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival

(2017) Bernhard Mlecnik et al.   JNCI-Journal of the National Cancer Institute

QuPath: Open source software for digital pathology image analysis

(2017) Peter Bankhead et al.   Scientific Reports

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

(2016) Willy Hugo et al.   CELL

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

(2016) Alexander M.M. Eggermont et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy

(2016) Nayoung Lee et al.   PATHOLOGY

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

(2015) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association BetweenNRASandBRAFMutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma

(2015) Nancy E. Thomas et al.   JAMA Oncology

Dissection of Immune Gene Networks in Primary Melanoma Tumors Critical for Antitumor Surveillance of Patients with Stage II–III Resectable Disease

(2014) Shanthi Sivendran et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Tumor-Infiltrating Lymphocyte Grade in Primary Melanomas Is Independently Associated With Melanoma-Specific Survival in the Population-Based Genes, Environment and Melanoma Study

(2013) Nancy E. Thomas et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor-Infiltrating Lymphocyte Grade Is an Independent Predictor of Sentinel Lymph Node Status and Survival in Patients With Cutaneous Melanoma

(2012) Farhad Azimi et al.   JOURNAL OF CLINICAL ONCOLOGY

A High Proliferative Index of Recurrent Melanoma Is Associated with Worse Survival

(2011) Ting J. Tu et al.   ONCOLOGY

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study

(2010) S. J. O'Day et al.   ANNALS OF ONCOLOGY

Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma

(2010) Rita G Ladstein et al.   BMC CANCER

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma

(2009) J. Weber et al.   CLINICAL CANCER RESEARCH